OBJECTIVE: Low-grade gliomas (LGGs) are infiltrative tumors characterized by slow growth. However, during early period, LGGs can progress and transform into a malignant pathology. We analyzed the prognostic factors for progression and malignant transformation in LGGs. MATERIALS AND METHODS:From 2000 to 2009, we operated on 86 patients: 42 oligodendrogliomas, 12 oligoastrocytomas, and 32 astrocytomas. The male:female ratio was 47:39, and the median age was 41 (±17.4) years. The mean follow-up period was 4.25 (±2.8) years. We analyzed the prognostic factors for progression-free survival (PFS), overall survival (OS), and malignant transformation, considering age, sex, KPS, clinical presentation, tumor location, radiologic pattern, extent of removal, pathologic subtype, and adjuvant treatment. RESULTS: In univariate analysis, non-eloquent location, gross total removal, and oligodendroglial pathology statistically correlated with improved PFS and OS. In multivariate analysis, gross total removal correlated with longer PFS (p=0.043), and gemistocytic astrocytoma had a poor PFS (p=0.004). Younger age and non-eloquent area showed an improved OS (p=0.002 and 0.041), and astrocytic pathology showed a poor OS (p=0.01). Malignant transformation was pathologically diagnosed in 13 out of 86 patients (15%). Gemistocytic astrocytoma correlated independently with malignant transformation (p=0.022). CONCLUSION: In LGGs, extent of removal associated with tumor progression. The pathology of astrocytoma, especially gemistocytic astrocytoma, was an independent prognostic factor for recurrence and malignant transformation.
RCT Entities:
OBJECTIVE: Low-grade gliomas (LGGs) are infiltrative tumors characterized by slow growth. However, during early period, LGGs can progress and transform into a malignant pathology. We analyzed the prognostic factors for progression and malignant transformation in LGGs. MATERIALS AND METHODS: From 2000 to 2009, we operated on 86 patients: 42 oligodendrogliomas, 12 oligoastrocytomas, and 32 astrocytomas. The male:female ratio was 47:39, and the median age was 41 (±17.4) years. The mean follow-up period was 4.25 (±2.8) years. We analyzed the prognostic factors for progression-free survival (PFS), overall survival (OS), and malignant transformation, considering age, sex, KPS, clinical presentation, tumor location, radiologic pattern, extent of removal, pathologic subtype, and adjuvant treatment. RESULTS: In univariate analysis, non-eloquent location, gross total removal, and oligodendroglial pathology statistically correlated with improved PFS and OS. In multivariate analysis, gross total removal correlated with longer PFS (p=0.043), and gemistocytic astrocytoma had a poor PFS (p=0.004). Younger age and non-eloquent area showed an improved OS (p=0.002 and 0.041), and astrocytic pathology showed a poor OS (p=0.01). Malignant transformation was pathologically diagnosed in 13 out of 86 patients (15%). Gemistocytic astrocytoma correlated independently with malignant transformation (p=0.022). CONCLUSION: In LGGs, extent of removal associated with tumor progression. The pathology of astrocytoma, especially gemistocytic astrocytoma, was an independent prognostic factor for recurrence and malignant transformation.
Authors: Daphne Meza; Danni Wang; Yu Wang; Sabine Borwege; Nader Sanai; Jonathan T C Liu Journal: Lasers Surg Med Date: 2015-04-14 Impact factor: 4.025
Authors: Maya Harary; Vasileios K Kavouridis; Matthew Torre; Hasan A Zaidi; Ugonma N Chukwueke; David A Reardon; Timothy R Smith; J Bryan Iorgulescu Journal: Neuro Oncol Date: 2020-03-05 Impact factor: 12.300
Authors: Ryan S Youland; Cole R Kreofsky; David A Schomas; Paul D Brown; Jan C Buckner; Nadia N Laack Journal: J Neurooncol Date: 2017-08-23 Impact factor: 4.130
Authors: Brian V Nahed; Navid Redjal; Daniel J Brat; Andrew S Chi; Kevin Oh; Tracy T Batchelor; Timothy C Ryken; Steven N Kalkanis; Jeffrey J Olson Journal: J Neurooncol Date: 2015-11-03 Impact factor: 4.130
Authors: Elena Jansen; Christina Hamisch; Daniel Ruess; Dieter Henrik Heiland; Roland Goldbrunner; Maximilian I Ruge; Oliver Schnell; Stefan J Grau Journal: J Neurooncol Date: 2019-10-16 Impact factor: 4.130
Authors: Timothy J Brown; Daniela A Bota; Martin J van Den Bent; Paul D Brown; Elizabeth Maher; Dawit Aregawi; Linda M Liau; Jan C Buckner; Michael Weller; Mitchel S Berger; Michael Glantz Journal: Neurooncol Pract Date: 2018-08-18
Authors: Manish K Aghi; Brian V Nahed; Andrew E Sloan; Timothy C Ryken; Steven N Kalkanis; Jeffrey J Olson Journal: J Neurooncol Date: 2015-11-03 Impact factor: 4.130